Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ANIP NASDAQ:IVA NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.72+1.2%$37.74$23.42▼$62.58$2.13B0.87719,213 shs577,000 shsANIPANI Pharmaceuticals$97.55-1.3%$80.19$52.50▼$99.50$2.12B0.63375,379 shs460,786 shsIVAInventiva$5.33+0.4%$4.20$1.53▼$6.50$509.88M0.6824,145 shs9,376 shsRXRXRecursion Pharmaceuticals$4.84+1.5%$5.34$3.79▼$12.36$2.10B0.9124.00 million shs21.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-1.31%-0.30%-1.92%+4.64%-22.25%ANIPANI Pharmaceuticals+1.13%+3.79%+12.96%+55.97%+68.88%IVAInventiva-5.35%-1.12%+21.79%+58.74%+137.05%RXRXRecursion Pharmaceuticals-1.24%+3.25%-17.33%-1.45%-27.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.72+1.2%$37.74$23.42▼$62.58$2.13B0.87719,213 shs577,000 shsANIPANI Pharmaceuticals$97.55-1.3%$80.19$52.50▼$99.50$2.12B0.63375,379 shs460,786 shsIVAInventiva$5.33+0.4%$4.20$1.53▼$6.50$509.88M0.6824,145 shs9,376 shsRXRXRecursion Pharmaceuticals$4.84+1.5%$5.34$3.79▼$12.36$2.10B0.9124.00 million shs21.26 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-1.31%-0.30%-1.92%+4.64%-22.25%ANIPANI Pharmaceuticals+1.13%+3.79%+12.96%+55.97%+68.88%IVAInventiva-5.35%-1.12%+21.79%+58.74%+137.05%RXRXRecursion Pharmaceuticals-1.24%+3.25%-17.33%-1.45%-27.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$56.0052.51% UpsideANIPANI Pharmaceuticals 3.10Buy$88.25-9.53% DownsideIVAInventiva 2.83Moderate Buy$14.83178.30% UpsideRXRXRecursion Pharmaceuticals 2.40Hold$7.2549.79% UpsideCurrent Analyst Ratings BreakdownLatest IVA, AGIO, ANIP, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$86.00 ➝ $114.009/4/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M58.45N/AN/A$27.02 per share1.36ANIPANI Pharmaceuticals$614.38M3.45$7.59 per share12.86$19.11 per share5.10IVAInventiva$9.20M55.43N/AN/A($1.21) per share-4.40RXRXRecursion Pharmaceuticals$58.84M35.71N/AN/A$2.61 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.34N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$0.77N/A23.17N/A-1.37%25.03%8.00%11/14/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest IVA, AGIO, ANIP, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ANIPANI Pharmaceuticals1.392.541.96IVAInventivaN/A0.920.92RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AANIPANI Pharmaceuticals76.05%IVAInventiva19.06%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ANIPANI Pharmaceuticals12.70%IVAInventiva32.00%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableIVA, AGIO, ANIP, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should KnowSeptember 16 at 5:42 AM | msn.comGoldman Sachs Group Inc. Has $7.91 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 16 at 4:10 AM | marketbeat.comNeedham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8September 15 at 11:25 AM | msn.comStock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)September 13 at 2:39 AM | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.7% Higher - Here's What HappenedSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)September 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Receives "Buy" Rating from Needham & Company LLCSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLCSeptember 12, 2025 | americanbankingnews.comRecursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc.September 10, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comRussell Investments Group Ltd. Has $206,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 4, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comJump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRXAugust 29, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 AcquisitionAugust 28, 2025 | insidermonkey.comRecursion to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLCAugust 25, 2025 | marketbeat.comNeedham Maintains Buy Rating on Recursion (RXRX)August 24, 2025 | msn.comThe Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to ExplodeAugust 23, 2025 | fool.comRecursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.August 23, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Caught a Cold This WeekAugust 22, 2025 | fool.comRecursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025August 22, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025IVA, AGIO, ANIP, and RXRX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.72 +0.42 (+1.16%) Closing price 04:00 PM EasternExtended Trading$36.72 0.00 (-0.01%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.ANI Pharmaceuticals NASDAQ:ANIP$97.55 -1.26 (-1.28%) Closing price 04:00 PM EasternExtended Trading$97.60 +0.05 (+0.05%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Inventiva NASDAQ:IVA$5.33 +0.02 (+0.38%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Recursion Pharmaceuticals NASDAQ:RXRX$4.84 +0.07 (+1.47%) Closing price 04:00 PM EasternExtended Trading$4.84 +0.00 (+0.10%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
